Bronchitis News and Research RSS Feed - Bronchitis News and Research

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
LINX Reflux Management System safe for patients suffering from GERD, shows new data

LINX Reflux Management System safe for patients suffering from GERD, shows new data

Torax Medical today announced the release of new data from two leading U.S. medical centers that further establishes the LINX Reflux Management System as a safe and effective procedure for patients suffering from gastroesophageal reflux disease (GERD). [More]
Motivational interviewing reduces secondhand smoke exposure among children living in households

Motivational interviewing reduces secondhand smoke exposure among children living in households

A Johns Hopkins-led research team has found that motivational interviewing, along with standard education and awareness programs, significantly reduced secondhand smoke exposure among children living in those households. [More]
Researchers develop virtual platform that measures level of addiction of smokers

Researchers develop virtual platform that measures level of addiction of smokers

In Mexico, 21.7 percent of the population smokes, which is associated with 95 percent of 
lung cancer cases and the development of 29 more different conditions. [More]
FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. [More]
Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD). [More]
FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). [More]
GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study. [More]
Study shows commonly used statin drug does not reduce acute COPD exacerbations

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA. [More]
Children who wheeze are at risk of developing damage that affect lung function

Children who wheeze are at risk of developing damage that affect lung function

Children who wheeze are at risk of developing damage that will affect their lung function by the age of 6 years, according to researchers at CHU Sainte-Justine Hospital and the University of Montreal. [More]
Study: Electronic cigarette "vapors" may worsen acute respiratory diseases among youth

Study: Electronic cigarette "vapors" may worsen acute respiratory diseases among youth

Electronic cigarette "vapors" are made of small particles containing chemicals that may cause or worsen acute respiratory diseases, including asthma and bronchitis, among youth, according to a new study by RTI International. [More]
GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GlaxoSmithKline plc and Theravance, Inc. today announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US. [More]
Researchers launch detailed atlas with environment and health maps

Researchers launch detailed atlas with environment and health maps

Researchers have launched a detailed atlas with environment and health maps at a fine scale across England and Wales. [More]
Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza. [More]
Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy". [More]
Scientists discover new protein that is involved in cancer, inflammation in lung tissue

Scientists discover new protein that is involved in cancer, inflammation in lung tissue

Scientists from The University of Manchester - part of the Manchester Cancer Research Centre (MCRC) - have discovered a new protein that is involved in cancer and inflammation in lung tissue. [More]
COPD sufferers can reduce risk of being hospitalized by walking 3 kilometers a day

COPD sufferers can reduce risk of being hospitalized by walking 3 kilometers a day

New research in Respirology shows that suffers of Chronic obstructive pulmonary disease (COPD) can reduce their risk of being hospitalized with severe attacks, by maintaining an exercise regime of walking between three to six kilometers a day. [More]
Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients. [More]
Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis Inc. today reported its financial results for the fourth quarter and full year 2013. The company reported revenue of $1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012. Revenue reflected an operational increase of 9%, with foreign currency having a negative impact of 2 percentage points. [More]
Geranium plant extracts prevent HIV-1 from invading human cells

Geranium plant extracts prevent HIV-1 from invading human cells

Extracts of the geranium plant Pelargonium sidoides inactivate human immunodeficiency virus type 1 (HIV-1) and prevent the virus from invading human cells. In the current issue of "PLOS ONE", scientists from the Helmholtz Zentrum München report that these extracts represent a potential new class of anti-HIV-1 agents for the treatment of AIDS. [More]